Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

SHE:300497 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	471.51	482.98	695.35	729.37	978.03	1,272
Trading Asset Securities	0.82	0.95	2.19	2.19	49.74	150.76
Cash & Short-Term Investments	472.32	483.93	697.54	731.56	1,028	1,423
Cash Growth	-26.51%	-30.62%	-4.65%	-28.82%	-27.79%	-15.88%
Accounts Receivable	619.32	533.29	498.16	572.92	552.49	376.21
Other Receivables	30.64	47.35	53.85	128.31	78.21	80.01
Receivables	649.96	580.64	552.01	701.23	630.71	456.22
Inventory	381.66	379.93	421.05	434.68	553.69	416.15
Other Current Assets	45.26	16.84	10.42	9.97	17.11	15.97
Total Current Assets	1,549	1,461	1,681	1,877	2,229	2,312
Property, Plant & Equipment	2,276	2,290	2,267	2,331	2,201	1,857
Long-Term Investments	193.25	271.31	255.9	271.27	271.42	133.02
Goodwill	-	-	-	-	1.15	2.22
Other Intangible Assets	285.64	287.85	235	241.07	249.71	256.32
Long-Term Deferred Tax Assets	35.04	34.8	37.26	29.37	28.49	27.54
Other Long-Term Assets	140.63	59.69	60.95	69.13	78.79	90.82
Total Assets	4,479	4,405	4,537	4,819	5,060	4,678

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	322.47	348.04	603.37	581.93	656.67	517.05
Accrued Expenses	13.22	36.71	44.05	44.52	42.4	51.97
Short-Term Debt	731.5	571.5	556.4	549.83	366.74	615.18
Current Portion of Long-Term Debt	69.34	270.02	311.78	78.78	7.96	33.5
Current Income Taxes Payable	13.87	0.06	0.05	0.82	8.71	13.89
Current Unearned Revenue	3.92	2.43	2.72	3.4	1.42	1.82
Other Current Liabilities	115.49	40.49	25.46	26.32	174.96	126.56
Total Current Liabilities	1,270	1,269	1,544	1,286	1,259	1,360
Long-Term Debt	815.44	809.46	736.48	998.26	1,043	353
Long-Term Unearned Revenue	123.21	123.97	77.67	62.39	62.03	50.3
Long-Term Deferred Tax Liabilities	1.84	1.86	1.96	2.05	6.27	3.92
Total Liabilities	2,210	2,205	2,360	2,348	2,370	1,767

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	538.65	538.65	550	550	550	550
Additional Paid-In Capital	1,249	1,247	1,381	1,414	1,408	1,406
Retained Earnings	414.95	353.75	408.78	680.88	881.68	1,023
Treasury Stock	-	-	-174.86	-174.86	-174.86	-105.11
Comprehensive Income & Other	44.59	44.33	15.45	14.3	16.89	6.08
Total Common Equity	2,247	2,184	2,180	2,485	2,681	2,880
Minority Interest	22.23	16.38	-3.54	-14.06	8.4	31.1
Shareholders' Equity	2,269	2,200	2,177	2,471	2,690	2,911
Total Liabilities & Equity	4,479	4,405	4,537	4,819	5,060	4,678

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	1,616	1,651	1,605	1,627	1,418	1,002
Net Cash (Debt)	-1,144	-1,167	-907.13	-895.31	-389.97	421.54
Net Cash Growth	-	-	-	-	-	-66.26%
Net Cash Per Share	-2.10	-2.12	-1.70	-1.65	-0.72	0.78
Filing Date Shares Outstanding	538.65	538.65	538.65	538.65	538.65	538.65
Total Common Shares Outstanding	538.65	538.65	538.65	538.65	538.65	543.13
Working Capital	279.4	192.09	137.2	591.84	970.42	951.59
Book Value Per Share	4.17	4.05	4.05	4.61	4.98	5.30
Tangible Book Value	1,961	1,896	1,945	2,244	2,430	2,622
Tangible Book Value Per Share	3.64	3.52	3.61	4.17	4.51	4.83
Buildings	-	1,030	936.67	836.72	712.09	471.86
Machinery	-	1,773	1,641	1,423	1,232	851.39
Construction In Progress	-	428.95	457.86	695.78	736.4	922.19

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error